Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 12/20 | 0.45 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508018 | 0.87 | NLRP3 (0.44) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19508014 | 0.87 | NLRP3 (0.56) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20932975 | 0.83 | NLRP3 (0.45) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507374 | 0.82 | NLRP3 (0.52) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507064 | 0.82 | NLRP3 (0.41) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507054 | 0.80 | NLRP3 (0.46) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507113 | 0.80 | NLRP3 (0.46) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL20932979 | 0.79 | NLRP3 (0.45) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19508015 | 0.78 | NLRP3 (0.41) | NLRP3SOAT2MYCSOAT1MAP2K3 | |
| SCHEMBL19507115 | 0.77 | NLRP3 (0.44) | NLRP3SOAT2MYCSOAT1MAP2K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445749-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-12-21 | — | — | EP | disclosed |
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2019-04-25 | — | — | US | disclosed |
| WO-2017184604-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM THERAPEUTICS, INC (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119241-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | NLRP3 2/4885SOAT2 2587/4885MYC 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.